James T. McCracken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James T. McCracken has a total of 308 co-authors. Here are the top co-authors by number of shared publications:
- Jeremy Veenstra-VanderWeele
Columbia University
4 shared publications - Gregory L. Hanna
Department of Psychiatry, University of Michigan, Ann Arbor MI, USA
3 shared publications - Jack Samuels
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA
3 shared publications - John Piacentini
Division of Child and Adolescent Psychiatry, Jane & Terry Semel Institute For Neurosciences, University of California, Los Angeles, CA, USA
3 shared publications - Abby J. Fyer
Department of Psychiatry, New York State Psychiatric Institute
2 shared publications - Abdel Abdellaoui
Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 31 March 2026
- Published by Elsevier in Psychiatry Research
- Vol. 361, 117135
Early life adversity, inhibitory control, and behavioral dysregulation among individuals with OCD
- 31 March 2026
- Published by Elsevier in Psychiatry Research
- Vol. 361, 117135
Early life adversity, inhibitory control, and behavioral dysregulation among individuals with OCD
- Open Access
- 16 October 2024
- Published by Elsevier in JAACAP Open
- Vol. 3 (4) , 863-874
Unmasking and Addressing COVID-19–Related Maladaptive Grief Reactions Among Suicidal Youth: Pilot Evidence for an Enhanced Psychiatry Emergency Room Safety Preventive Intervention
- 16 October 2024
- Published by Elsevier in JAACAP Open
- Vol. 3 (4) , 863-874
Open AccessUnmasking and Addressing COVID-19–Related Maladaptive Grief Reactions Among Suicidal Youth: Pilot Evidence for an Enhanced Psychiatry Emergency Room Safety Preventive Intervention
- Open Access
Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) affects ∼1% of children and adults and is partly caused by genetic factors. We conducted a genome-wide association study (GWAS) meta-analysis combining 53,660 OCD cases and 2,044,417 controls and identified 30 independent genome-wide significant loci. Gene-based approaches identified 249 potential effector genes for OCD, with 25 of these classified as the most likely causal candidates, including WDR6, DALRD3, CTNND1 and multiple genes in the MHC region. We estimated that ∼11,500 genetic variants explained 90% of OCD genetic heritability. OCD genetic risk was associated with excitatory neurons in the hippocampus and cortex, along with D1- and D2-type dopamine receptor-containing medium spiny neurons. OCD genetic risk was shared with 65 of 112 additional phenotypes, including all of the psychiatric disorders we examined. In particular, OCD shared genetic risk with anxiety, depression, anorexia nervosa, and Tourette syndrome, and was negatively associated with inflammatory bowel diseases, educational attainment, and body mass index.
Open AccessGenome-wide analyses identify 30 loci associated with obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) affects ∼1% of children and adults and is partly caused by genetic factors. We conducted a genome-wide association study (GWAS) meta-analysis combining 53,660 OCD cases and 2,044,417 controls and identified 30 independent genome-wide significant loci. Gene-based approaches identified 249 potential effector genes for OCD, with 25 of these classified as the most likely causal candidates, including WDR6, DALRD3, CTNND1 and multiple genes in the MHC region. We estimated that ∼11,500 genetic variants explained 90% of OCD genetic heritability. OCD genetic risk was associated with excitatory neurons in the hippocampus and cortex, along with D1- and D2-type dopamine receptor-containing medium spiny neurons. OCD genetic risk was shared with 65 of 112 additional phenotypes, including all of the psychiatric disorders we examined. In particular, OCD shared genetic risk with anxiety, depression, anorexia nervosa, and Tourette syndrome, and was negatively associated with inflammatory bowel diseases, educational attainment, and body mass index.
- Open Access
- 10 August 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (4) , 415-426
Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder
- 10 August 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (4) , 415-426
Open AccessElectrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder
- Open Access
- 9 August 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (1) , 37-47
Methylphenidate, Guanfacine, and Combined Treatment Effects on Electroencephalography Correlates of Spatial Working Memory in Attention-Deficit/Hyperactivity Disorder
- 9 August 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (1) , 37-47
Open AccessMethylphenidate, Guanfacine, and Combined Treatment Effects on Electroencephalography Correlates of Spatial Working Memory in Attention-Deficit/Hyperactivity Disorder
- Open Access
- 11 June 2022
- Published by Springer Nature in Molecular Autism
- Vol. 13 (1) , 1-11
Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program
Background: Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that is characterized by the core symptoms of social communication difficulties and restricted and repetitive behaviors. At present, there is an unmet medical need for therapies to ameliorate these core symptoms in order to improve quality of life of autistic individuals. However, several challenges are currently faced by the ASD community relating to the development of pharmacotherapies, namely in the conduct of clinical trials. Balovaptan is a V1a receptor antagonist that has been investigated to improve social communication difficulties in individuals with ASD. In this viewpoint, we draw upon our recent first-hand experiences of the balovaptan clinical development program to describe current challenges of ASD trials. Discussion points: The balovaptan trials were conducted in a wide age range of individuals with ASD with the added complexities associated with international trials. When summarizing all three randomized trials of balovaptan, a placebo response was observed across several outcome measures. Placebo response was predicted by greater baseline symptom severity, online recruitment of participants, and less experienced or non-academic trial sites. We also highlight challenges relating to selection of outcome measures in ASD, the impact of baseline characteristics, and the role of expectation bias in influencing trial results. Conclusion: Taken together, the balovaptan clinical development program has advanced our understanding of the key challenges facing ASD treatment research. The insights gained can be used to inform and improve the design of future clinical trials with the collective aim of developing efficacious therapies to support individuals with ASD.
- 11 June 2022
- Published by Springer Nature in Molecular Autism
- Vol. 13 (1) , 1-11
Open AccessLarge multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program
Background: Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that is characterized by the core symptoms of social communication difficulties and restricted and repetitive behaviors. At present, there is an unmet medical need for therapies to ameliorate these core symptoms in order to improve quality of life of autistic individuals. However, several challenges are currently faced by the ASD community relating to the development of pharmacotherapies, namely in the conduct of clinical trials. Balovaptan is a V1a receptor antagonist that has been investigated to improve social communication difficulties in individuals with ASD. In this viewpoint, we draw upon our recent first-hand experiences of the balovaptan clinical development program to describe current challenges of ASD trials. Discussion points: The balovaptan trials were conducted in a wide age range of individuals with ASD with the added complexities associated with international trials. When summarizing all three randomized trials of balovaptan, a placebo response was observed across several outcome measures. Placebo response was predicted by greater baseline symptom severity, online recruitment of participants, and less experienced or non-academic trial sites. We also highlight challenges relating to selection of outcome measures in ASD, the impact of baseline characteristics, and the role of expectation bias in influencing trial results. Conclusion: Taken together, the balovaptan clinical development program has advanced our understanding of the key challenges facing ASD treatment research. The insights gained can be used to inform and improve the design of future clinical trials with the collective aim of developing efficacious therapies to support individuals with ASD.
- Open Access
Genome-wide association study identifies new locus associated with OCD
Obsessive-compulsive disorder (OCD) is a heritable disorder, but no definitive, replicated OCD susceptibility loci have yet been identified by any genome-wide association study (GWAS). Here, we report results from a GWAS in the largest OCD case-control sample (N = 14,140 OCD cases and N = 562,117 controls) to date. We explored the genetic architecture of OCD, including its genetic relationships to other psychiatric and non-psychiatric phenotypes. In the GWAS analysis, we identified one SNP associated with OCD at a genome-wide significant level. Subsequent gene-based analyses identified additional two genes as potentially implicated in OCD pathogenesis. All SNPs combined explained 16% of the heritability of OCD. We show sub-stantial positive genetic correlations between OCD and a range of psychiatric disorders, including anxiety disorders, anorexia nervosa, and major depression. We thus for the first time provide evidence of a genome-wide locus implicated in OCD and strengthen previous literature suggesting a polygenic nature of this disorder.
Open AccessGenome-wide association study identifies new locus associated with OCD
Obsessive-compulsive disorder (OCD) is a heritable disorder, but no definitive, replicated OCD susceptibility loci have yet been identified by any genome-wide association study (GWAS). Here, we report results from a GWAS in the largest OCD case-control sample (N = 14,140 OCD cases and N = 562,117 controls) to date. We explored the genetic architecture of OCD, including its genetic relationships to other psychiatric and non-psychiatric phenotypes. In the GWAS analysis, we identified one SNP associated with OCD at a genome-wide significant level. Subsequent gene-based analyses identified additional two genes as potentially implicated in OCD pathogenesis. All SNPs combined explained 16% of the heritability of OCD. We show sub-stantial positive genetic correlations between OCD and a range of psychiatric disorders, including anxiety disorders, anorexia nervosa, and major depression. We thus for the first time provide evidence of a genome-wide locus implicated in OCD and strengthen previous literature suggesting a polygenic nature of this disorder.
- 13 June 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (1) , 399-410
Morning light therapy in adults with Tourette’s disorder
Background Sleep disturbance is common among individuals with Tourette’s Disorder (TD). Given that sleep is influenced by the circadian system, this study examined circadian rhythms and sleep in adults with TD, and explored the possible benefit of short-wavelength wearable morning light therapy. Methods Participants were 34 adults with TD (n = 14) and age- and sex-matched healthy controls (HC; n = 20). Participants were screened using clinician-rated diagnostic and tic severity interviews, and procedures lasted 3 consecutive weeks. Participants completed a baseline week of actigraphy. Adults with TD completed 2 weeks of Re-Timer™ morning light therapy and continued actigraphy monitoring. Dim light melatonin-onset (DLMO) phase assessment, tic severity interview, and measures of chronotype, sleep disturbance, daytime sleepiness, disability, depression, anxiety, and stress were completed at baseline and post-intervention. Results Adults with TD reported significantly greater eveningness and sleep disturbance relative to controls. Per wrist actigraphy, adults with TD exhibited significantly longer sleep-onset latency, lower sleep efficiency, and greater sleep fragmentation than HC. Following morning light therapy, there was a significant advance in DLMO phase, but not self-report or actigraphy sleep variables. There were small, statistically significant decreases in tic severity and impairment. There were also significant reductions in daytime sleepiness, and self-reported anxiety, but not depression, stress, or disability. Participants reported minimal side effects and rated light therapy as acceptable and comfortable. Conclusions Findings showed some benefits following brief light therapy in TD; further exploration of the impact of spectral tuning the photic environment as part of treatment for TD subjects is warranted.
- 13 June 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (1) , 399-410
Morning light therapy in adults with Tourette’s disorder
Background Sleep disturbance is common among individuals with Tourette’s Disorder (TD). Given that sleep is influenced by the circadian system, this study examined circadian rhythms and sleep in adults with TD, and explored the possible benefit of short-wavelength wearable morning light therapy. Methods Participants were 34 adults with TD (n = 14) and age- and sex-matched healthy controls (HC; n = 20). Participants were screened using clinician-rated diagnostic and tic severity interviews, and procedures lasted 3 consecutive weeks. Participants completed a baseline week of actigraphy. Adults with TD completed 2 weeks of Re-Timer™ morning light therapy and continued actigraphy monitoring. Dim light melatonin-onset (DLMO) phase assessment, tic severity interview, and measures of chronotype, sleep disturbance, daytime sleepiness, disability, depression, anxiety, and stress were completed at baseline and post-intervention. Results Adults with TD reported significantly greater eveningness and sleep disturbance relative to controls. Per wrist actigraphy, adults with TD exhibited significantly longer sleep-onset latency, lower sleep efficiency, and greater sleep fragmentation than HC. Following morning light therapy, there was a significant advance in DLMO phase, but not self-report or actigraphy sleep variables. There were small, statistically significant decreases in tic severity and impairment. There were also significant reductions in daytime sleepiness, and self-reported anxiety, but not depression, stress, or disability. Participants reported minimal side effects and rated light therapy as acceptable and comfortable. Conclusions Findings showed some benefits following brief light therapy in TD; further exploration of the impact of spectral tuning the photic environment as part of treatment for TD subjects is warranted.
- 1 October 2020
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 59 (10) , S163-S164
6.14 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER
- 1 October 2020
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 59 (10) , S163-S164
6.14 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER
- 1 October 2017
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 56 (10) , S176-S177
2.2 Trial of Positive Psychiatry in Comorbid Attention-Deficit Hyperactive/Disorder (ADHD) With Posttraumatic Stress Disorder (PTSD)
- 1 October 2017
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 56 (10) , S176-S177
2.2 Trial of Positive Psychiatry in Comorbid Attention-Deficit Hyperactive/Disorder (ADHD) With Posttraumatic Stress Disorder (PTSD)